Announced
Completed
Financials
Tags
Acquisition
Majority
Single Bidder
United Kingdom
health care
Pharmaceuticals
pharma
Cross Border
Public
Friendly
Completed
Synopsis
Danaher, a global science and technology innovator, completed the acquisition of Abcam, a global supplier of protein consumables, for $5.7bn. "We couldn't be more excited to have Abcam join Danaher. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio positions them as a key partner for the scientific community. We look forward to welcoming Abcam's innovative and talented team to Danaher as we continue to help our customers solve some of the world's biggest healthcare challenges," Rainer M. Blair, Danaher President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.